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To the Editor,
We were interested to read the report by Yang et al,
“A clinical trial of 3 doses of transdermal 17β-estradiol
for preventing postmenopausal bone loss: a prelimi-
nary study”.1 The authors provided a useful clinical
observation, showing that the use of low-dose estra-
diol gel at the dose of 1.25 g/day (equivalent to 17β-
estradiol 0.75 mg/day) could effectively prevent bone
loss in postmenopausal women after a 12-month
treatment period.
We were greatly concerned, however, about the
recommendation from the authors. Postmenopausal
osteoporosis following vertebral and/or non-vertebral
fracture is an important health issue because it results
in a significant increase in morbidity and mortality in
postmenopausal women. For decades, conventional
hormone therapy (HT), mainly with estrogen plus
progestin (EPT), has been the mainstay therapy not
only for relieving climacteric symptoms but also for
preventing and treating postmenopausal osteoporosis.2
However, because the significant risk is greater than the
benefit, with a resultant low acceptable benefit/risk
ratio, HT should not be recommended as a therapeutic
strategy for preventing and treating osteoporosis in rou-
tine practice in postmenopausal women without vaso-
motor symptoms.3 We were disappointed to read the
authors’ positive recommendation of HT for the cardio-
vascular system. In the text, the authors commented that
HT could reduce morbidity and mortality from cardio-
vascular disease, although the authors cited 4 published
articles to support their recommendation. From the
results of the Women’s Health Initiative (WHI), one
can conclude that, in women with osteoporosis and
cardiovascular risk factors, HT should be avoided in
favor of alternative antiresorptive agents,4 and that HT
remains an option only for short-term early use around
the menopause in symptomatic younger women with
high risk of fracture.4 The post-WHI turmoil was
actually focused on the risks of therapy, although data
from more recent publications “surprisingly” indicated
that risk may vary with type of hormone, dosage, route
of administration, duration of treatment, and patient
age, suggesting that the use of HT and the increased
cardiovascular risk is still doubtful.5–7
We are interested to know why the authors used
estriol 2 mg/day as their control group. A number of
small-scale trials of poor methodologic design have
been conducted to assess the efficacy of estriol, which
is widely used in Japan and Europe as HT, mostly
together with other estrogens, for the treatment of
urogenital atrophy or climacteric symptoms.8 The effec-
tiveness of the treatment of climacteric symptoms with
estriol use only is doubtful. In addition, 3 studies failed
to detect significant protection from bone loss,9–12
although 2 other studies favored the effectiveness of
bone protection in the use of estriol.13,14
Finally, we do not agree with the authors’ conclu-
sion that the therapeutic effect of estradiol gel on bone
mass was more prominent in the surgical menopausal
groups at the dosage of 2.5 g/day. In addition, we
look forward to learning the reason why the authors
suggested the effectiveness dose of estradiol gel as
1.25 g/day. From either Figure 1 or Figure 2, the most
effective dose for increasing bone mass density was
5 g/day.1 We already know the fact that the increased
bone mass density is not equal to the increased bone
quality.15
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To the Editor,
We would like to respond to the letter from Wen-Ling
Lee, Hsiang-Tai Chao and Peng-Hui Wang. First, thank
you for your important comments on our paper.
Second, you mention that recent randomized clin-
ical trials of postmenopausal hormone therapy (HT)
have informed clinical decision-making, but several
key questions remain unanswered. Observation stud-
ies suggest that HT prevents coronary heart disease
